Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.

Yoshida H, Kim YH, Ozasa H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Yamamoto T, Ajimizu H, Hirai T.

In Vivo. 2018 Nov-Dec;32(6):1587-1590. doi: 10.21873/invivo.11418.

2.

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH.

Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31.

PMID:
30171175
3.

Nivolumab in non-small-cell lung cancer with EGFR mutation.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Funazo T, Hirai T.

Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745. No abstract available.

PMID:
29161357
4.

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

Tsuji T, Sakamori Y, Ozasa H, Yagi Y, Ajimizu H, Yasuda Y, Funazo T, Nomizo T, Yoshida H, Nagai H, Maeno K, Oguri T, Hirai T, Kim YH.

Oncotarget. 2017 May 16;8(42):71805-71816. doi: 10.18632/oncotarget.17895. eCollection 2017 Sep 22.

5.

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Yasuda Y, Nomizo T, Ozasa H, Funazo T, Tsuji T, Yoshida H, Sakamori Y, Nagai H, Handa T, Kubo T, Kim YH.

Mol Clin Oncol. 2017 Oct;7(4):677-680. doi: 10.3892/mco.2017.1373. Epub 2017 Aug 11.

6.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.

Funazo T, Nomizo T, Kim YH.

J Thorac Oncol. 2017 Sep;12(9):e140-e141. doi: 10.1016/j.jtho.2017.04.027. No abstract available.

7.

Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Yasuda Y, Nishikawa Y, Sakamori Y, Terao M, Hashimoto K, Funazo T, Nomizo T, Tsuji T, Yoshida H, Nagai H, Ozasa H, Hirai T, Kim YH.

Mol Clin Oncol. 2017 Aug;7(2):295-297. doi: 10.3892/mco.2017.1310. Epub 2017 Jun 29.

8.

EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Funazo T, Yasuda Y, Hirai T.

Anticancer Res. 2017 May;37(5):2721-2725.

PMID:
28476851
9.

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai H, Hirai T, Kim YH.

Sci Rep. 2017 Mar 23;7:45124. doi: 10.1038/srep45124.

10.

Effects of D-allulose on glucose metabolism after the administration of sugar or food in healthy dogs.

Nishii N, Nomizo T, Takashima S, Matsubara T, Tokuda M, Kitagawa H.

J Vet Med Sci. 2016 Dec 1;78(11):1657-1662. Epub 2016 Jul 22.

11.

Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Nakaoku T, Yagi Y, Tsuji T, Nomizo T, Mishima M.

Mol Clin Oncol. 2016 Jul;5(1):213-215. Epub 2016 May 6.

12.

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

Shima H, Ozasa H, Tsuji T, Ajimizu H, Nomizo T, Yagi Y, Sakamori Y, Nagai H, Minamiguchi S, Kim YH, Mishima M.

Mol Clin Oncol. 2016 May;4(5):715-718. Epub 2016 Mar 7.

13.

Single oral dose safety of D-allulose in dogs.

Nishii N, Nomizo T, Takashima S, Matsubara T, Tokuda M, Kitagawa H.

J Vet Med Sci. 2016 Jul 1;78(6):1079-83. doi: 10.1292/jvms.15-0676. Epub 2016 Mar 14.

14.

[A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib].

Kobayashi Y, Emura M, Nakamura T, Cho T, Seto R, Nomura N, Nomizo T, Igarashi S.

Kekkaku. 2013 Sep;88(9):671-5. Japanese.

PMID:
24298694

Supplemental Content

Loading ...
Support Center